Nektar Therapeutics' CEO, Howard Robin, is pleased with the ...
Nektar Therapeutics' CEO, Howard Robin, is pleased with the deal, stating it strengthens the company's finances and extends its cash runway to Q3 2026. He also emphasized the potential of rezpegaldesleukin, a novel biologic in Phase 2b studies.
Press Release: Nektar Therapeutics Announces $30 Million Private Placement Financing With TCGX
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment